Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYCLOVIR vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Herpes simplex virus (HSV) infections: genital herpes, herpes labialis, herpes simplex encephalitis, neonatal herpes,Varicella-zoster virus (VZV) infections: chickenpox, herpes zoster (shingles),Mucocutaneous HSV infections in immunocompromised patients,Prophylaxis of HSV and VZV infections in immunocompromised patients
Management of mild to moderate pain,Reduction of fever
400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life is 2.5–3.3 hours in adults with normal renal function; increases to 19.5 hours in anuria.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Acyclovir is partially metabolized by alcohol and aldehyde dehydrogenase. The major metabolite is 9-carboxymethoxymethylguanine (CMMG), which is inactive. Hepatic metabolism is minimal, and the drug is predominantly excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 62-90% of elimination. Fecal elimination is <2%.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
9–33% bound to plasma proteins (albumin).
10-25% bound to albumin at therapeutic concentrations.
Vd: 0.5–1.5 L/kg. Distributes widely; crosses blood-brain barrier achieving 50% of plasma CSF concentration.
0.8-1.0 L/kg; suggests distribution into total body water.
Oral: 15–30% (dose-dependent). Topical: Minimal systemic absorption (<5%).
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Cr Cl >25 m L/min: no adjustment; Cr Cl 10-25 m L/min: standard dose every 12 hours; Cr Cl <10 m L/min: standard dose every 24 hours.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
No dose adjustment required for hepatic impairment; no Child-Pugh based modifications established.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Neonates: 10-20 mg/kg intravenously every 8 hours; Children: 250-600 mg/m² orally 3-5 times daily or 5-10 mg/kg intravenously every 8 hours.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Adjust based on renal function; start at low end of dosing range; monitor for neurotoxicity.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
None. Acyclovir does not have a black box warning.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Renal impairment: Dose adjustment required for Cr Cl < 50 m L/min; risk of acute renal failure due to crystallization in renal tubules, especially with rapid IV infusion or dehydration,Neurologic toxicity: Elderly patients or those with renal impairment may develop CNS effects (agitation, hallucinations, seizures); use with caution,Hematologic: Rare reports of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in immunocompromised patients,IV administration: Avoid rapid infusion, ensure adequate hydration to prevent renal damage
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hypersensitivity to acyclovir or valacyclovir,Lactation: Caution advised; excreted in breast milk
Hypersensitivity to acetaminophen or any component of the formulation
No significant food interactions. High-fat meals may reduce absorption but not clinically significant. Avoid excessive alcohol as it may worsen side effects (e.g., dizziness).
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defects compared to the general population. However, high-dose IV acyclovir in first trimester for severe infections carries theoretical risk; use only if clearly needed. No known specific fetal risks by trimester beyond those of the underlying infection.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Acyclovir is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.6 to 4.1. An exclusively breastfed infant would receive 0.1-1% of maternal dose (or 0.3-0.7 mg/kg/day based on typical maternal 200 mg oral dose), which is below neonatal therapeutic doses. American Academy of Pediatrics considers acyclovir compatible with breastfeeding. Monitor infant for rash or gastrointestinal disturbance.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
Pregnancy does not significantly alter acyclovir pharmacokinetics; no dose adjustment needed for oral or IV acyclovir. Standard dosing regimens for HSV (e.g., 200-400 mg PO TID for genital herpes or 5-10 mg/kg IV q8h for severe infection) are used. In third trimester, increased renal clearance may require slightly higher doses for VZV (typically 800 mg PO 5 times/day), but no formal recommendations for dose increase. Always adjust for renal impairment separately.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Acyclovir requires adequate hydration to prevent crystalluria and nephrotoxicity; ensure urine output >500 m L/q8h. For IV acyclovir, infuse over at least 1 hour to avoid renal damage. Dose adjustment required in renal impairment (Cr Cl <50 m L/min). Early initiation (within 72 hours of rash) improves outcomes in herpes zoster. Oral acyclovir has low bioavailability (15-30%); valacyclovir is a prodrug with better absorption.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take acyclovir exactly as prescribed, even if symptoms improve.,Drink plenty of water during treatment to prevent kidney problems.,Start medication at the first sign of outbreak for best results.,Do not share your medication with others.,Avoid sexual contact when lesions are present to prevent transmission.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYCLOVIR vs INJECTAPAP, answered by our medical review team.
ACYCLOVIR is a Antiviral that works by Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYCLOVIR and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYCLOVIR is: 400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYCLOVIR and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYCLOVIR is classified as Category A/B. Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defec. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.